Samsung Biologics' History, CEO, Future, Stock Price Analysis

Samsung Biologics is an affiliate of Samsung Group established in 2011 for the purpose of consignment production (CMO) of biopharmaceuticals. Customers have global pharmaceutical companies that lack their own production capabilities or strategically outsource production to focus their business on drug R&D and marketing.

1. History of Samsung BioLogics

Samsung Biologics History, Samsung Biologics was established as a joint venture between Samsung Electronics and Samsung C&T on December 28, 2011. It started its business in earnest on January 1, 2013, and was listed on the New York Stock Exchange on December 17 of that year. Samsung BioLogics operates a production plant with a total floor area of 330,000 pyeong in Songdo, Incheon. Plant 1 was completed in December 2013, followed by Plant 2 in December 2015 and Plant 3 in April 2018. The company aims to operate a fourth plant with the world's largest production capacity based on a single plant in 2023. Samsung Biologics has a global pharmaceutical company that lacks its own production capabilities or strategically outsources production to focus its business capabilities on drug R&D and marketing. Major clients include Roche, Bristol Myers Squibb (BMS), Johnson & Johnson and Eli Lilly. Samsung Biologics achieved record-high earnings in 2021 with sales of 2.4372 trillion won and operating profit of 1.3893 trillion won. It is also growing into a global CMO company by topping the global CMO market share in 2022.

2. CEO of Samsung Biologics

CEO of Samsung Biologics, CEO of Samsung Biologics is John Lim. He is a global biopharmaceutical expert with a master's degree in chemical engineering in the United States and a master's degree in chemical engineering in the Northwestern, and has served as production, sales, and development director and CFO at Roche/Genentech. President John Lim joined Samsung Biologics in September 2018 and oversaw the operation of the third plant, the world's largest biopharmaceutical factory, and achieved results in securing orders and stabilizing early even in the COVID19 situation. He has been the CEO of Samsung BioLogics since March 2021.

3. Future of Samsung Biologics

Samsung Biologics Mirae, Samsung Biologics is the world's largest biopharmaceutical consignment (CMO) company. Since its establishment in 2011, it has grown rapidly and now has more than 30 customers, including Global Big Pharma. Samsung BioLogics' growth was mainly due to its high technology, production capacity, and customer-centered services. Samsung Biologics is expected to continue to grow. The biopharmaceutical market is a high-growth market that grows more than 10% annually, and Samsung BioLogics is expected to benefit from this market. In addition, Samsung Biologics is expected to secure new growth engines by entering new therapeutic fields such as antibody drug conjugation (ADC) and gene therapy, which are next-generation anticancer drugs. The future of Samsung BioLogics is bright. Based on its high technology, production capacity, and customer-centered service, it is expected to grow into the world's No. 1 CMO company.

4. Samsung Biologics Stock Price Analysis

Samsung BioLogics shares have been on the decline since rising to 800,000 won in August 2021. The reasons for the fall in stock prices include slowing growth in the biopharmaceutical market, the investment burden caused by Samsung BioLogics' expansion of new factories, and concerns over a global economic slowdown. However, Samsung BioLogics is still considered one of the most competitive companies in the biopharmaceutical market. Samsung Biologics has the world's largest biopharmaceutical factory and is gaining the trust of global big Pharma with its high technology and customer-centered services. In addition, Samsung Biologics is securing new growth engines by entering new therapeutic fields such as antibody drug conjugation (ADC) and gene therapy, which are next-generation anticancer drugs. As a result, Samsung BioLogics' stock price is expected to rise in the long run. However, in the short term, volatility may exist, such as slowing growth in the biopharmaceutical market and concerns over a global economic slowdown. Therefore, it is desirable to take a long-term approach to investing in Samsung Biologics stocks.

samsung, samsung biologics